HSF1

Heat shock factor protein 1 · Q00613 · HSF1 on Sugi Atlas →

4,321 patent compounds predicted against HSF1, 2,500 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3069489	0.62	16/20
SCHEMBL3069491	0.62	16/20
Hydrochloric Acid (SCHEMBL3059702)	0.62	15/20
Hydrochloric Acid (SCHEMBL3059703)	0.62	15/20
SCHEMBL3060495	0.60	15/20
SCHEMBL3060503	0.60	15/20
SCHEMBL3079628	0.55	15/20
SCHEMBL3079630	0.55	15/20
SCHEMBL3565918	0.55	15/20
Arimoclomol (SCHEMBL196123)	0.54	15/20
Arimoclomol (SCHEMBL1896428)	0.54	15/20
Arimoclomol (SCHEMBL2324741)	0.54	15/20
Arimoclomol (SCHEMBL5699241)	0.54	15/20
Arimoclomol (SCHEMBL5699251)	0.53	15/20
Arimoclomol (SCHEMBL5699253)	0.53	15/20
Arimoclomol (SCHEMBL7052423)	0.53	15/20
SCHEMBL9426850	0.60	14/20
SCHEMBL9426852	0.60	14/20
Hydrochloric Acid (SCHEMBL3060651)	0.57	14/20
Hydrochloric Acid (SCHEMBL3060654)	0.57	14/20

Clinical trials — most relevant to HSF1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Symbicort ® on GR in Sputum in COPD	PHASE4	COMPLETED
OGX-427 in Castration Resistant Prostate Cancer Patients	PHASE2	COMPLETED
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)	PHASE1/PHASE2	COMPLETED
Targeting the Tumor Microenvironment in R/M SCCHN	PHASE1/PHASE2	UNKNOWN
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas	PHASE1	COMPLETED
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies	PHASE1	WITHDRAWN
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma	PHASE1	COMPLETED
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma	PHASE1	COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer	PHASE1	COMPLETED
Perfusion-Induced Hyperthermia for Metastatic Carcinoma	nan	COMPLETED
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC	nan	COMPLETED
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk	nan	COMPLETED
Cardioprotective Benefit of Passive Heat Therapy in Higher-Level Spinal Cord Injury: Safety and Proof of Concept	nan	UNKNOWN
Acute Passive Heating in Healthy Older Adults	nan	COMPLETED
RFA for Malignant Biliary Obstruction	nan	UNKNOWN
Chronic Passive Heating in Healthy Older Adults	nan	COMPLETED
Trial of Nonsurgical Treatment of Intermittent Claudication Due to Femoro-popliteal Disease	nan	COMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Clinical Implications of FKBP5 in Stroke	nan	UNKNOWN
Chronic Heat Therapy for Improving Vascular Health	nan	COMPLETED
The Role of HSP90 in Peripheral Vascular Lesions of Diabetic Atherosclerosis	nan	COMPLETED
Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer	nan	UNKNOWN
Molecular Hydrogen Inhalation: Effects on Health, Exercise Capacity and Inflammatory Response - in Vivo/in Vitro Studies	nan	NOT_YET_RECRUITING
Reduced Ventilator-Free Days and Bacterial Colonization of Sub-Glottic Secretions	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a HSF1 binder may also engage these)

Protein	Name	Similarity
P38532	—	1.000	P38532 →
P41154	—	0.998	P41154 →
Q08DJ8	—	0.998	Q08DJ8 →
P38529	—	0.991	P38529 →
Q5CZP2	—	0.991	Q5CZP2 →
P38531	—	0.989	P38531 →
Q9Z136	—	0.989	Q9Z136 →
NFRKB	Nuclear factor related to kappa-B-binding protein	0.987	landscape →
Q9EP53	—	0.987	Q9EP53 →
A0M8T5	—	0.986	A0M8T5 →
Q2IBA2	—	0.986	Q2IBA2 →
Q09YK4	—	0.985	Q09YK4 →
Q8TE85	—	0.985	Q8TE85 →
Q8AXV6	—	0.985	Q8AXV6 →
Q09YG9	—	0.985	Q09YG9 →
Q3U1N2	—	0.985	Q3U1N2 →
Q6PIJ4	—	0.985	Q6PIJ4 →
Q5RIX9	—	0.985	Q5RIX9 →
Q00PJ1	—	0.985	Q00PJ1 →
Q09YJ3	—	0.985	Q09YJ3 →
Q80Y50	—	0.985	Q80Y50 →
Q09YM8	—	0.985	Q09YM8 →
Q6PCQ0	—	0.984	Q6PCQ0 →
O94983	—	0.984	O94983 →
Q8VDP4	—	0.984	Q8VDP4 →
F6VAN0	—	0.984	F6VAN0 →
Q92574	—	0.984	Q92574 →
O70405	—	0.984	O70405 →
Q80XS6	—	0.984	Q80XS6 →
A1X157	—	0.984	A1X157 →